Wall Street analysts will be watching closely when Quest Diagnostics Incorporated (NYSE:DGX) reports its quarterly earnings next, which is scheduled for Thu 14 Feb (In 32 Days). Looking at the latest analyst forecasts, the current earnings-per-share (EPS) consensus estimate is sitting at $1.80 per share. In the preceding quarter, the company reportedly generated EPS of $1.68 per share of its common stock. Looking at profitability indicators, this organization has an operating margin of 15.10%, a profit margin of 11.30% and a gross margin of 36.90%.
Speaking of Wall Street analysts, a number of market experts at top investment banks have recently posted their updated ratings on shares of Quest Diagnostics Incorporated (NYSE:DGX). Most recently, on January 3rd, 2019, BofA/Merrill Downgrade a Underperform rating. Before that, on December 3rd, 2018, BofA/Merrill Downgrade to Neutral. Goldman Downgrade a Neutral rating on November 30th, 2018, BofA/Merrill Resumed an Buy rating on October 19th, 2018, and Evercore ISI Upgrade a Outperform rating on July 10th, 2018.
At its current price point, combined with the fact that this company has 136.00M shares outstanding, the current market capitalization sits at 11.56B. In the last trading day, 1,098,131 shares of Quest Diagnostics Incorporated were traded, which compares to its usual volume of about 1.41M shares per day of trading.
If we compare this company’s current price to its recent pricing activity, we can see that the price has changed by $2.32 in the past five trading days, resulting in a percentage change of +2.80% and a moving average of 84.21. In the past 20 days, its price changed by -$3.25 (which is -3.68%) and the stock’s moving average was 83.35. Looking back a full 50 days, shares of DGX changed by -$6.80 (which is -7.40%) and demonstrated a moving average of 89.21.
Staying in the same analytical area, this company’s stock has demonstrated a 9-day Stochastic %K score of 85.47%, a 14-day Stochastic %K score of 87.38% and a 20-day Stochastic %K score of 55.67%. Using a similar metric, Quest Diagnostics Incorporated (DGX) shares showed a Stochastic %D of 86.47% over the past 9 days, a Stochastic %D score of 77.95% over the last 14 days, and a 20-day Stochastic %D of 51.25%. Meanwhile, this stock’s MACD Oscillator was 1.41 over the past 9 days, 2.01 over the past two weeks, and 1.38 in the last 20 days.
As recent trading data suggests, this company’s shares have been hovering close to the $85.03 level. Over the past 12 months, this stock has experienced a high price of $116.49 and a low of $78.95. Top market experts pay heightened attention to a stock as it is getting closer to a notable historic high price or low price.
The Vanguard Group Inc purchased more shares of this company during the last fiscal quarter, as we can observe in the latest corresponding filing from Quest Diagnostics Incorporated (NYSE:DGX) with the Securities and Exchange Commission (SEC). This specific major shareholder, at the end of the quarter, held 14,295,877 shares of the company’s stock following the addition of 200,079 to this investor’s holdings during the three-month period. This share count represents that The Vanguard Group Inc now held 10.51% stake in Quest Diagnostics Incorporated (DGX)’s shares.
Just in the most recent trading day, Quest Diagnostics Incorporated (NYSE:DGX) experienced a high price of $85.13 and low point of $84.11. At the end of the last trading session, this stock was at 85.03 per share, following a loss of -$0.48, or 0.35% during the full day.